Non-concurrent controls in platform trials: can we borrow their concurrent observation data?

IF 1.5 4区 医学 Q3 MATHEMATICAL & COMPUTATIONAL BIOLOGY Statistics in Biopharmaceutical Research Pub Date : 2023-10-05 DOI:10.1080/19466315.2023.2267502
Ziren Jiang, Cindy Lu, Jialing Liu, Satrajit Roychoudhury, Daniel Meyer, Bo Huang, Haitao Chu
{"title":"Non-concurrent controls in platform trials: can we borrow their concurrent observation data?","authors":"Ziren Jiang, Cindy Lu, Jialing Liu, Satrajit Roychoudhury, Daniel Meyer, Bo Huang, Haitao Chu","doi":"10.1080/19466315.2023.2267502","DOIUrl":null,"url":null,"abstract":"AbstractAdaptive platform trials (APTs) offer an innovative approach to studying multiple therapeutic interventions more efficiently through flexible features such as adding and dropping interventions as evidence emerges, creating a seamless process that avoids enrollment disruption. The benefits and practical challenges of implementing APTs have been widely discussed in the literature; however, less consideration has been given to how to use the non-concurrent control (NCC) data (i.e., the data generated by patients recruited in the control arm before a new treatment is added) when the outcome of interest is a time to event endpoint. Including the NCC can increase the power of the trial. However, due to the omnipresent change of standard care over time, complete borrowing of the NCC survival data may lead to some bias in the estimation. In this paper, we propose an alternative approach to borrow the concurrent observation part of the NCC data by left truncation using a simple decision-making flowchart, which can reduce the bias due to the change of standard care under certain assumptions. Then, the restricted mean survival time (RMST), estimated by the Kaplan-Meier method, is used to compare the treatment versus the pooled control group. We present two simulation studies to illustrate the performance of the decision-making flowchart method under different scenarios. We advocate researchers and drug developers to apply and validate this simple approach in practice.Key Words: platform trialnon-concurrent controlrestricted mean survival timeKaplan-Meier methodmaster protocolDisclaimerAs a service to authors and researchers we are providing this version of an accepted manuscript (AM). Copyediting, typesetting, and review of the resulting proofs will be undertaken on this manuscript before final publication of the Version of Record (VoR). During production and pre-press, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal relate to these versions also. FundingThe author(s) reported there is no funding associated with the work featured in this article.","PeriodicalId":51280,"journal":{"name":"Statistics in Biopharmaceutical Research","volume":"54 1","pages":"0"},"PeriodicalIF":1.5000,"publicationDate":"2023-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Statistics in Biopharmaceutical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/19466315.2023.2267502","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MATHEMATICAL & COMPUTATIONAL BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

AbstractAdaptive platform trials (APTs) offer an innovative approach to studying multiple therapeutic interventions more efficiently through flexible features such as adding and dropping interventions as evidence emerges, creating a seamless process that avoids enrollment disruption. The benefits and practical challenges of implementing APTs have been widely discussed in the literature; however, less consideration has been given to how to use the non-concurrent control (NCC) data (i.e., the data generated by patients recruited in the control arm before a new treatment is added) when the outcome of interest is a time to event endpoint. Including the NCC can increase the power of the trial. However, due to the omnipresent change of standard care over time, complete borrowing of the NCC survival data may lead to some bias in the estimation. In this paper, we propose an alternative approach to borrow the concurrent observation part of the NCC data by left truncation using a simple decision-making flowchart, which can reduce the bias due to the change of standard care under certain assumptions. Then, the restricted mean survival time (RMST), estimated by the Kaplan-Meier method, is used to compare the treatment versus the pooled control group. We present two simulation studies to illustrate the performance of the decision-making flowchart method under different scenarios. We advocate researchers and drug developers to apply and validate this simple approach in practice.Key Words: platform trialnon-concurrent controlrestricted mean survival timeKaplan-Meier methodmaster protocolDisclaimerAs a service to authors and researchers we are providing this version of an accepted manuscript (AM). Copyediting, typesetting, and review of the resulting proofs will be undertaken on this manuscript before final publication of the Version of Record (VoR). During production and pre-press, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal relate to these versions also. FundingThe author(s) reported there is no funding associated with the work featured in this article.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
平台试验中的非并发控制:我们可以借用他们的并发观察数据吗?
摘要自适应平台试验(APTs)提供了一种创新的方法,通过灵活的特征,如随着证据的出现增加和减少干预措施,更有效地研究多种治疗干预措施,创造了一个无缝的过程,避免了入组中断。实施APTs的好处和实际挑战已在文献中广泛讨论;然而,很少考虑如何使用非并发对照(NCC)数据(即在添加新治疗之前在对照组招募的患者产生的数据),当感兴趣的结果是到事件终点的时间。包括NCC可以增加审判的权力。然而,由于标准护理随着时间的推移而无处不在地发生变化,完全借用NCC生存数据可能会导致估计存在一些偏差。在本文中,我们提出了一种替代方法,通过简单的决策流程图左截断借用NCC数据的并发观测部分,可以减少在某些假设下由于标准关怀变化而引起的偏差。然后,使用Kaplan-Meier法估计的限制平均生存时间(RMST)来比较治疗组与合并对照组。我们通过两个仿真研究来说明决策流程图方法在不同场景下的性能。我们提倡研究人员和药物开发人员在实践中应用和验证这种简单的方法。关键词:平台试验非并发对照限制平均生存时间kaplan - meier方法主协议免责声明作为对作者和研究人员的服务,我们提供此版本的已接受稿件(AM)。在最终出版版本记录(VoR)之前,将对该手稿进行编辑、排版和审查。在制作和印前,可能会发现可能影响内容的错误,所有适用于期刊的法律免责声明也与这些版本有关。作者报告说,没有与本文所述工作相关的资金。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Statistics in Biopharmaceutical Research
Statistics in Biopharmaceutical Research MATHEMATICAL & COMPUTATIONAL BIOLOGY-STATISTICS & PROBABILITY
CiteScore
3.90
自引率
16.70%
发文量
56
期刊介绍: Statistics in Biopharmaceutical Research ( SBR), publishes articles that focus on the needs of researchers and applied statisticians in biopharmaceutical industries; academic biostatisticians from schools of medicine, veterinary medicine, public health, and pharmacy; statisticians and quantitative analysts working in regulatory agencies (e.g., U.S. Food and Drug Administration and its counterpart in other countries); statisticians with an interest in adopting methodology presented in this journal to their own fields; and nonstatisticians with an interest in applying statistical methods to biopharmaceutical problems. Statistics in Biopharmaceutical Research accepts papers that discuss appropriate statistical methodology and information regarding the use of statistics in all phases of research, development, and practice in the pharmaceutical, biopharmaceutical, device, and diagnostics industries. Articles should focus on the development of novel statistical methods, novel applications of current methods, or the innovative application of statistical principles that can be used by statistical practitioners in these disciplines. Areas of application may include statistical methods for drug discovery, including papers that address issues of multiplicity, sequential trials, adaptive designs, etc.; preclinical and clinical studies; genomics and proteomics; bioassay; biomarkers and surrogate markers; models and analyses of drug history, including pharmacoeconomics, product life cycle, detection of adverse events in clinical studies, and postmarketing risk assessment; regulatory guidelines, including issues of standardization of terminology (e.g., CDISC), tolerance and specification limits related to pharmaceutical practice, and novel methods of drug approval; and detection of adverse events in clinical and toxicological studies. Tutorial articles also are welcome. Articles should include demonstrable evidence of the usefulness of this methodology (presumably by means of an application). The Editorial Board of SBR intends to ensure that the journal continually provides important, useful, and timely information. To accomplish this, the board strives to attract outstanding articles by seeing that each submission receives a careful, thorough, and prompt review. Authors can choose to publish gold open access in this journal.
期刊最新文献
A Basket Trial Design Based on Power Priors Remembering Gregory Campbell (1949-2023): An Accomplished Leader, Mentor, and Biostatistical Innovator Combining Recurrent and Terminal Events Into a Composite Endpoint May Be Problematic Simultaneous Confidence Intervals for Signal Detection and Ascertaining Precision of Adverse Event Rates in Clinical Trials Bayesian shrinkage estimation of credible subgroups for count data with excess zeros
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1